Hi-Tech Pharmacal Acquires Rights to the Cormax Brand for its ECR Pharmaceuticals Subsidiary

Hi-Tech Pharmacal Co., Inc. HITK announced today the signing of a definitive agreement under which Hi-Tech acquired exclusive rights to the Cormax brand from Watson Laboratories for an undisclosed sum of money. Cormax, a branded version of clobetasol propionate topical solution 0.05%, is indicated for the treatment dermatoses of the scalp. The Cormax® brand will be sold through the Company's branded prescription subsidiary, ECR Pharmaceuticals. ECR will launch Cormax® in June 2012. The brand had sales of approximately $600,000 in 2011 according to IMS data.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsM&A
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!